Contact:
PRISM BioLab Co., Ltd.
info@prismbiolab.com

26-1, Muraoka-Higashi 2chome. Fujisawa,Kanagawa 251-8555
www.prismbiolab.com

PRESS RELEASEPRISM BioLab raises 1.5 billion yen in Series C fundraising to advancetechnologies and programs targeting protein-protein interactions
Eli Lilly and Company, Santec Holdings Corporation participated in the round
TOKYO, Japan, 24 January 2024: -- PRISM BioLab, Co. Ltd. (“PRISM”), a leading discovery and development
biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets,today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM’s proprietary
PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipelineof PPI inhibitors.
As the numbers of so called “druggable” targets are dwindling, pharma is gradually turning to PPI targets.
Due to frequent involvement in the disease and a sheer number of PPIs, they have long been recognized
as a new frontier for drug discovery but the progress has been hampered by the lack of chemistries thatcan successfully address PPI targets. PRISM BioLab has early recognized the importance of PPIs as drugtargets and has spent over a decade developing proprietary PepMetics® chemical scaffolds that mimic
three-dimensional structure of the alpha-helix and beta-turn, peptide structures commonly found in PPIinterphases. Today, PepMetics® chemistry enables systematic and reproducible discovery anddevelopment of drugs targeting PPIs.
"We are confident that our PepMetics® chemistry will become one of the key technologies for the PPItarget field," said Dai Takehara, CEO of PRISM BioLab. "The funds from this financing round will be used tointegrate our PepMetics® chemistry, biology and screening capabilities, to advance our internal pipeline,
and to provide greater value to our existing and future pharma partners. We recognize the importance ofpartnerships for the success of new approaches to drug discovery and are fortunate to build a long-term
relationship with Lilly, a top pharma company, as we move the field forward."
Comments from investors
Santec Holdings Corporation Executive Vice President & CTO Changho Chong Ph.D.
We feel confident that PRISM BioLab's promising and unique approach to drug discovery will lead tobreakthrough therapeutic drugs that were previously unattainable. Santec is engaged in the developmentof medical imaging devices and early diagnosis utilizing Photonics. We believe that the advancement of

these technologies, in conjunction with innovative drug discovery techniques, is pivotal for thecomprehensive improvement of patients’ Quality of Life (QoL).
About PRISM BioLab
PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics®
technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets
and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics®
are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn,the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By
combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics®
technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand thefield of drug discovery by turning previously undruggable PPIs into targets readily druggable with small
molecules and by generating oral small molecule alternatives for injectable biologics.
PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies.
PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals Co.,
Ltd. are in clinical development for cancer and liver disease, respectively.
www.prismbiolab.com